This discovery reveals previously unrecognized anti-inflammatory mechanisms of HSC, suggesting that its therapeutic strategy involving TLR4 modulation for AKI diverges from conventional clinical approaches such as dialysis and antibiotic therapies. The gene discussed is TLR4; the disease is acute kidney injury.